Earlier this week, Bristol-Myers Squibb signaled its continued focus on becoming the world’s most successful specialty pharmaceutical company, and a global oncology leader when it announced the acquisition of Flexus Biosciences for up to $1.25 billion, along with a $339 million research agreement with Rigel Pharmaceuticals.
So far this year there has been a lot in the news about M&A activity within the pharmaceutical industry, and lately the coverage seems to be about what’s happening with mid-tier companies, or specialty pharmaceutical companies. These companies are by no means small, but they aren’t on the same level as the top 10 global pharmaceutical companies. And they tend to be focused in markets where they have particular strengths.
This morning I read a very sad story in the excellent British newspaper The Telegraph. David Cameron, Prime Minister of the United Kingdom, described the “desperate sadness” he felt as he watched Margaret Thatcher, a brilliant politician and one of the UK’s great leaders who he saw at the height of her powers, slip away with the onset and progression of dementia.
The United Kingdom is in the midst of a national debate on dementia as the result of a recent report from the Care Quality Commission (CQC), the independent regulator of health and social care in England. The report found major shortcomings in the quality of care provided to those suffering from dementia across the country. Continue reading
Yesterday, Bloomberg announced that Merck KGaA will acquire Sigma-Aldrich, a leading global laboratory supply and drug manufacturing services organization for $17 billion in cash. According to Bloomberg, this most recent deal is part of a broader strategy for Merck KGaA to “reduce its dependence on drug development.”
As an avid student of history since I was young, I have been watching and thoroughly enjoying the Ken Burns series “The Roosevelts: An Intimate History” airing on PBS over the past few weeks. While many people have at least a basic understanding of, and appreciation for, the achievements of Franklin Delano Roosevelt, and his extraordinary wife and First Lady Eleanor Roosevelt, I think that far fewer of us are that knowledgeable about Theodore Roosevelt, simply because his presidency and his lifetime are to us far more distant history. But what a great man Theodore Roosevelt was. Burns’ outstanding program gives us wonderful insights into just how thoroughly modern Teddy Roosevelt was, in terms of really helping to shape our current understanding of sustainability, creating the foundations for today’s corporate America, and ushering in a new era of consumer protection by paving the way for what is today’s Food and Drug Administration.